Pricey Pfizer Drug Spurs Call For NIH Collaboration Probe

Law360, New York (March 20, 2013, 6:58 PM EDT) -- Sen. Ron Wyden, D-Ore., on Tuesday urged the National Institutes of Health to study whether drugmakers are benefiting excessively from public-private partnerships aimed at developing new medicines, prompting a furious pushback from Pfizer Inc., whose newly approved rheumatoid arthritis treatment got a lift from taxpayer-funded research.

Wyden released a letter he sent to the NIH last week spotlighting the roughly $25,000-per-year price tag of Pfizer's Xeljanz, or tofacitinib, arguing that when government researchers play a role in drug development, pharmaceutical companies have an obligation to return...
To view the full article, register now.